Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anika Therapeutics Inc (NASDAQ:ANIK)

45.82
Delayed Data
As of 12:20pm ET
 0.00 / 0.00%
Today’s Change
30.93
Today|||52-Week Range
54.96
+20.07%
Year-to-Date
AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
10:56am / Zacks.com - Paid Partner Content
Bayer (BAYRY) Strives for Increased Sales & Earnings Growth
Sep 20 / Zacks.com - Paid Partner Content
Ionis/Biogen Complete Nusinersen NDA Submission in U.S.
10:56am / Zacks.com - Paid Partner Content
Celgene Presents Efficacy & Safety Phase II Ozanimod Data
Sep 20 / Zacks.com - Paid Partner Content
Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S.
10:56am / Zacks.com - Paid Partner Content
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Sep 19 / Zacks.com - Paid Partner Content
Novartis Ilaris Approved for Extended Use in Periodic Fever
Sep 26 / Zacks.com - Paid Partner Content
Qiagen: Molecular Diagnostics & Expansion Plans on Track
Sep 16 / Zacks.com - Paid Partner Content
Achillion, J&J HCV Triple Combination Drug Data Presented
Sep 26 / Zacks.com - Paid Partner Content
Teva/Intel Tie up for Huntington's Disease Technology Platform
Sep 16 / Zacks.com - Paid Partner Content
Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
Sep 26 / Zacks.com - Paid Partner Content
Novavax Tanks, RSV F Vaccine Disappoints in Two Studies
Sep 16 / Zacks.com - Paid Partner Content
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb
Sep 26 / Zacks.com - Paid Partner Content
Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel
Sep 15 / Zacks.com - Paid Partner Content
Ligand Inks CNS License Agreement with Seelos Therapeutics
Sep 23 / Zacks.com - Paid Partner Content
Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Sep 15 / Zacks.com - Paid Partner Content
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Sep 23 / Zacks.com - Paid Partner Content
Bayer to Boost Agriculture Suite with $66B Monsanto Buyout
Sep 15 / Zacks.com - Paid Partner Content
The Medicines Co. to Get BARDA Funding for Infection Drugs
Sep 22 / Zacks.com - Paid Partner Content
Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan
Sep 15 / Zacks.com - Paid Partner Content
Gilead to Stop GS-5745 Development for Ulcerative Colitis
Sep 22 / Zacks.com - Paid Partner Content
Ligand (LGND) Commences Phase II Type II Diabetes Study
Sep 14 / Zacks.com - Paid Partner Content
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Sep 21 / Zacks.com - Paid Partner Content
Will Bayer (BAYRY) Raise its Monsanto Buyout Offer Again?
Sep 14 / Zacks.com - Paid Partner Content
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Sep 21 / Zacks.com - Paid Partner Content
Horizon (HZNP) to Acquire Raptor for $800M, Stock Soars
Sep 13 / Zacks.com - Paid Partner Content
Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Sep 21 / Zacks.com - Paid Partner Content
Repros Seeks EU Approval for Secondary Hypogonadism Drug
Sep 13 / Zacks.com - Paid Partner Content
Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Sep 20 / Zacks.com - Paid Partner Content
Celgene's Crohn's Disease Drug Positive in Phase Ib Study
Sep 13 / Zacks.com - Paid Partner Content
BioDelivery Bunavail Gets Better Managed Care Positioning
Sep 20 / Zacks.com - Paid Partner Content
J&J Files for Single-Tablet Regimen of HIV Drug Prezista in EU
Sep 13 / Zacks.com - Paid Partner Content
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Sep 20 / Zacks.com - Paid Partner Content